{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:01:56Z","timestamp":1782864116923,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kunin Chair in Women\u2019s Healthy Brain Aging"},{"name":"Brain and Genomics Fund"},{"name":"McKnight Presidential Chair"},{"name":"American Legion Brain Sciences Chair"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Blood biomarkers for dementia are being increasingly used for screening and possibly early detection of dementia in cognitively unimpaired (CU) people. Here we measured blood serum levels of 5 dementia-related biomarkers (A\u03b2<jats:sub>1\u201340<\/jats:sub> [A\u03b240], A\u03b2<jats:sub>1\u201342<\/jats:sub> [A\u03b242], A\u03b242\/A\u03b240 ratio, phosphorylated Tau181 [pTau181], and phosphorylated Tau217 [pTau217]) and determined the seroprevalence of 6 HHV (HHV1, HHV2, HHV3, HHV4, HHV5, HHV6) in 345 samples drawn at successive visits from 167 CU women 26\u201398\u00a0years old. All biomarkers except for A\u03b242\/A\u03b240 increased significantly with age, particularly in those who were HHV seropositive. With respect to the biomarkers, the increase was highest for A\u03b240\u2009&gt;\u2009A\u03b242\u2009&gt;\u2009pTau217\u2009&gt;\u2009pTau181, and, with respect to HHV, the increase was highest for HHV4\u2009&gt;\u2009HHV6\u2009&gt;\u2009HHV1\u2009&gt;\u2009HHV2\u2009&gt;\u2009HHV5 (HHV3 was seropositive in all samples). Overall, the average normalized rate of increase of biomarkers with age was 2.15\u2009\u00d7\u2009higher in the HHV seropositive vs. seronegative groups (P\u2009=\u20090.003, paired samples t-test). The presence of apolipoprotein E4 (apoE4) genotype did not have a significant effect on those rates. These findings document a link between prior viral infection and dementia-related blood biomarkers, adding support to the HHV hypothesis in developing dementia, irrespective of apoE4 allele presence.<\/jats:p>","DOI":"10.1038\/s41598-025-10102-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:49:32Z","timestamp":1752551372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human herpes viruses are associated with steeper age-dependent increases of serum biomarkers for dementia in cognitively unimpaired women"],"prefix":"10.1038","volume":"15","author":[{"given":"Lisa M.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Stratigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos P.","family":"Georgopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"10102_CR1","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter, W. J. et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977\u20131981. https:\/\/doi.org\/10.1073\/pnas.90.5.1977 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10102_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261, 921\u2013923. https:\/\/doi.org\/10.1126\/science.8346443 (1993).","journal-title":"Science"},{"key":"10102_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin, A. C. et al. ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol. Neurodegener. 17, 72. https:\/\/doi.org\/10.1186\/s13024-022-00574-4 (2022).","journal-title":"Mol. Neurodegener."},{"key":"10102_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jama.2019.9879","volume":"322","author":"I Lourida","year":"2019","unstructured":"Lourida, I. et al. Association of lifestyle and genetic risk with incidence of dementia. JAMA 322, 430\u2013437. https:\/\/doi.org\/10.1001\/jama.2019.9879 (2019).","journal-title":"JAMA"},{"key":"10102_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41582-018-0070-3","volume":"14","author":"M Kivipelto","year":"2018","unstructured":"Kivipelto, M., Mangialasche, F. & Ngandu, T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol. 14, 653\u2013666. https:\/\/doi.org\/10.1038\/s41582-018-0070-3 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"10102_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3233\/JAD-160152","volume":"51","author":"RF Itzhaki","year":"2016","unstructured":"Itzhaki, R. F. et al. Microbes and Alzheimer\u2019s disease. J. Alzheimers Dis. 51, 979\u2013984. https:\/\/doi.org\/10.3233\/JAD-160152 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR7","doi-asserted-by":"publisher","first-page":"102068","DOI":"10.1016\/j.arr.2023.102068","volume":"91","author":"F Bruno","year":"2023","unstructured":"Bruno, F. et al. Alzheimer\u2019s disease as a viral disease: Revisiting the infectious hypothesis. Ageing Res. Rev. 91, 102068. https:\/\/doi.org\/10.1016\/j.arr.2023.102068 (2023).","journal-title":"Ageing Res. Rev."},{"key":"10102_CR8","doi-asserted-by":"publisher","first-page":"e2550","DOI":"10.1002\/rmv.255025","volume":"34","author":"P Biagio","year":"2024","unstructured":"Biagio, P., Isabella, D. F., Federica, C., Elena, S. & Ivan, G. Alzheimer\u2019s disease and herpes viruses: Current events and perspectives. Rev. Med. Virol. 34, e2550. https:\/\/doi.org\/10.1002\/rmv.255025 (2024).","journal-title":"Rev. Med. Virol."},{"key":"10102_CR9","doi-asserted-by":"publisher","first-page":"e00324","DOI":"10.3389\/fnagi.2018.00324","volume":"10","author":"RF Itzhaki","year":"2018","unstructured":"Itzhaki, R. F. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer\u2019s disease. Front. Aging Neurosci. 10, e00324. https:\/\/doi.org\/10.3389\/fnagi.2018.00324 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"10102_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-031-31978-5_28","volume":"1423","author":"RF Itzhaki","year":"2023","unstructured":"Itzhaki, R. F. Infections, vaccinations, and risk of Alzheimer\u2019s disease (AD)\/dementia: Probable involvement of reactivated herpes simplex virus Type 1. Adv. Exp. Med. Biol. 1423, 279\u2013280. https:\/\/doi.org\/10.1007\/978-3-031-31978-5_28 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"key":"10102_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3233\/JAD-220287","volume":"88","author":"DM Cairns","year":"2022","unstructured":"Cairns, D. M., Itzhaki, R. F. & Kaplan, D. L. Potential involvement of varicella zoster virus in Alzheimer\u2019s disease via reactivation of quiescent herpes simplex virus type 1. J. Alzheimers Dis. 88, 1189\u20131200. https:\/\/doi.org\/10.3233\/JAD-220287 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00406-021-01311-6","volume":"272","author":"SW Lai","year":"2022","unstructured":"Lai, S. W., Kuo, Y. H. & Liao, K. F. Herpes zoster and Alzheimer\u2019s disease. Eur. Arch. Psychiatry Clin. Neurosci. 272, 923. https:\/\/doi.org\/10.1007\/s00406-021-01311-6 (2022).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10102_CR13","doi-asserted-by":"publisher","first-page":"16m11312","DOI":"10.4088\/JCP.16m11312","volume":"79","author":"VC Chen","year":"2018","unstructured":"Chen, V. C. et al. Herpes Zoster and dementia: A nationwide population-based cohort study. J. Clin. Psychiatry 79, 16m11312. https:\/\/doi.org\/10.4088\/JCP.16m11312 (2018).","journal-title":"J. Clin. Psychiatry"},{"key":"10102_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.29245\/2578-3009\/2021\/3.1218","volume":"5","author":"LM James","year":"2021","unstructured":"James, L. M., Charonis, S. A. & Georgopoulos, A. P. Association of dementia Human Leukocyte Antigen (HLA) profile with human herpes viruses 3 and 7: An in silico investigation. J. Immunol. Sci. 5, 7\u201314 (2021).","journal-title":"J. Immunol. Sci."},{"key":"10102_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neurobiolaging.2013.06.024","volume":"35","author":"I Carbone","year":"2013","unstructured":"Carbone, I. et al. Herpes virus in Alzheimer\u2019s disease: Relation to progression of the disease. Neurobiol. Aging 35, 122\u2013129. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.06.024 (2013).","journal-title":"Neurobiol. Aging"},{"key":"10102_CR16","first-page":"211","volume":"68","author":"S Charonis","year":"2020","unstructured":"Charonis, S., James, L. M. & Georgopoulos, A. P. In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens. Curr. Res. Transl. Med. 68, 211\u2013216 (2020).","journal-title":"Curr. Res. Transl. Med."},{"key":"10102_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neuron.2018.05.023","volume":"99","author":"B Readhead","year":"2018","unstructured":"Readhead, B. et al. Multiscale analysis of independent Alzheimer\u2019s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron 99, 64\u201382. https:\/\/doi.org\/10.1016\/j.neuron.2018.05.023 (2018).","journal-title":"Neuron"},{"key":"10102_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke, M. M. & Fowler, N. R. Alzheimer disease blood biomarkers: Considerations for population-level use. Nat. Rev. Neurol. 20, 495\u2013504. https:\/\/doi.org\/10.1038\/s41582-024-00989-1 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"10102_CR19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3 (2023).","journal-title":"Nat. Aging"},{"key":"10102_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085\u20131095. https:\/\/doi.org\/10.1038\/s41591-024-02869-z (2024).","journal-title":"Nat. Med."},{"key":"10102_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation. Lancet Neurol. 21, 66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6 (2022).","journal-title":"Lancet Neurol."},{"key":"10102_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332, 1245\u20131257. https:\/\/doi.org\/10.1001\/jama.2024.13855 (2024).","journal-title":"JAMA"},{"key":"10102_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia, J. et al. Biomarker changes during 20 years preceding Alzheimer\u2019s disease. NEJM 390, 712\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa2310168 (2024).","journal-title":"NEJM"},{"issue":"15","key":"10102_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/jama.2024.6619","volume":"332","author":"Y Lu","year":"2024","unstructured":"Lu, Y. et al. Changes in Alzheimer disease blood biomarkers and associations with incident all-cause dementia. JAMA 332(15), 1258\u20131269. https:\/\/doi.org\/10.1001\/jama.2024.6619 (2024).","journal-title":"JAMA"},{"key":"10102_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/DNND.S471174","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Advances in blood biomarkers for Alzheimer\u2019s disease: Ultra-sensitive detection technologies and impact on clinical diagnosis. Degener. Neurol. Neuromuscul. Dis. 14, 85\u2013102. https:\/\/doi.org\/10.2147\/DNND.S471174 (2024).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10102_CR26","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 19, 1913\u20131924. https:\/\/doi.org\/10.1002\/alz.12841 (2023).","journal-title":"Alzheimers Dement."},{"key":"10102_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau-and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013 (2018).","journal-title":"Alzheimers Dement."},{"key":"10102_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134 (2020).","journal-title":"JAMA"},{"key":"10102_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neubiorev.2021.07.007","volume":"128","author":"Y Qu","year":"2021","unstructured":"Qu, Y. et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 128, 479\u2013486. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.07.007 (2021).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10102_CR30","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen, N. C. et al. Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat. Commun. 12, 3555. https:\/\/doi.org\/10.1038\/s41467-021-23746-0 (2021).","journal-title":"Nat. Commun."},{"key":"10102_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-024-01459-y","volume":"16","author":"HE Dark","year":"2024","unstructured":"Dark, H. E. et al. Alzheimer\u2019s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Alzheimer\u2019s Res. Ther. 16, 94. https:\/\/doi.org\/10.1186\/s13195-024-01459-y (2024).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10102_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso, A. et al. Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 78, 396\u2013406. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4986 (2021).","journal-title":"JAMA Neurol."},{"issue":"4","key":"10102_CR33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80(4), 360\u2013369. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272 (2023).","journal-title":"JAMA Neurol."},{"key":"10102_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher, A. E. et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease. Alzheimers Dement. 5, 18\u201329. https:\/\/doi.org\/10.1016\/j.jalz.2008.10.004 (2009).","journal-title":"Alzheimers Dement."},{"key":"10102_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","volume":"23","author":"A Bradford","year":"2009","unstructured":"Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P. & Singh, H. Missed and delayed diagnosis of dementia in primary care: Prevalence and contributing factors. Alzheimer Dis. Assoc. Disord. 23, 306\u2013314. https:\/\/doi.org\/10.1097\/WAD.0b013e3181a6bebc (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10102_CR36","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686. https:\/\/doi.org\/10.1002\/alz.12756 (2022).","journal-title":"Alzheimers Dement."},{"key":"10102_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/alz.14203","volume":"2024","author":"CM Erickson","year":"2024","unstructured":"Erickson, C. M., Largent, E. A. & O\u2019Brien, K. S. Paving the way for Alzheimer\u2019s disease blood-based biomarkers in primary care. Alzheimers Dement. 2024, 1\u20137. https:\/\/doi.org\/10.1002\/alz.14203 (2024).","journal-title":"Alzheimers Dement."},{"key":"10102_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/JAD-143189","volume":"50","author":"M Kleinschmidt","year":"2016","unstructured":"Kleinschmidt, M. et al. Characterizing aging, mild cognitive impairment, and dementia with blood-based biomarkers and neuropsychology. J. Alzheimers Dis. 50, 111\u2013126. https:\/\/doi.org\/10.3233\/JAD-143189 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR39","doi-asserted-by":"publisher","first-page":"698571","DOI":"10.3389\/fnagi.2021.698571","volume":"13","author":"C Zecca","year":"2021","unstructured":"Zecca, C. et al. The role of age on beta-amyloid1-42 plasma levels in healthy subjects. Front. Aging Neurosci. 13, 698571. https:\/\/doi.org\/10.3389\/fnagi.2021.698571 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"10102_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-2011-101977","volume":"26","author":"F Song","year":"2011","unstructured":"Song, F. et al. Meta-analysis of plasma amyloid-\u03b2 levels in Alzheimer\u2019s disease. J. Alzheimers Dis. 26, 365\u2013375. https:\/\/doi.org\/10.3233\/JAD-2011-101977 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR41","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis, E. M. et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 5, fcad057. https:\/\/doi.org\/10.1093\/braincomms\/fcad057 (2023).","journal-title":"Brain Commun."},{"key":"10102_CR42","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241. https:\/\/doi.org\/10.1093\/brain\/awaa286 (2020).","journal-title":"Brain"},{"key":"10102_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 297, 353\u2013356. https:\/\/doi.org\/10.1126\/science.1072994 (2002).","journal-title":"Science"},{"key":"10102_CR44","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 78, 1375\u20131382. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180 (2021).","journal-title":"JAMA Neurol."},{"key":"10102_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11065-014-9267-4","volume":"24","author":"EC Mormino","year":"2014","unstructured":"Mormino, E. C. The relevance of beta-amyloid on markers of Alzheimer\u2019s disease in clinically normal individuals and factors that influence these associations. Neuropsychol. Rev. 24, 300\u2013312. https:\/\/doi.org\/10.1007\/s11065-014-9267-4 (2014).","journal-title":"Neuropsychol. Rev."},{"key":"10102_CR46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1474-4422(14)70194-2","volume":"13","author":"CR Jack Jr","year":"2014","unstructured":"Jack, C. R. Jr. et al. Age-specific population frequencies of cerebral \u03b2-amyloidosis and neurodegeneration among people with normal cognitive function aged 50\u201389 years: A cross-sectional study. Lancet Neurol. 13, 997\u20131005. https:\/\/doi.org\/10.1016\/S1474-4422(14)70194-2 (2014).","journal-title":"Lancet Neurol."},{"key":"10102_CR47","doi-asserted-by":"publisher","first-page":"e9505","DOI":"10.1371\/journal.pone.0009505","volume":"5","author":"SJ Soscia","year":"2010","unstructured":"Soscia, S. J. et al. The Alzheimer\u2019s disease-associated amyloid \u03b2-protein is an antimicrobial peptide. PLoS ONE 5, e9505. https:\/\/doi.org\/10.1371\/journal.pone.0009505 (2010).","journal-title":"PLoS ONE"},{"key":"10102_CR48","doi-asserted-by":"publisher","first-page":"340ra72","DOI":"10.1126\/scitranslmed.aaf1059","volume":"8","author":"DK Kumar","year":"2016","unstructured":"Kumar, D. K. et al. Amyloid-\u03b2 peptide protects against microbial infection in mouse and worm models of Alzheimer\u2019s disease. Sci. Transl. Med. 8, 340ra72. https:\/\/doi.org\/10.1126\/scitranslmed.aaf1059 (2016).","journal-title":"Sci. Transl. Med."},{"key":"10102_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2018.06.030","volume":"99","author":"WA Eimer","year":"2018","unstructured":"Eimer, W. A. et al. Alzheimer\u2019s disease-associated \u03b2-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 99, 56\u201363. https:\/\/doi.org\/10.1016\/j.neuron.2018.06.030 (2018).","journal-title":"Neuron"},{"key":"10102_CR50","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3233\/JAD-171133","volume":"62","author":"ML Gosztyla","year":"2018","unstructured":"Gosztyla, M. L., Brothers, H. M. & Robinson, S. R. Alzheimer\u2019s amyloid-\u03b2 is an antimicrobial peptide: A review of the evidence. J. Alzheimers Dis. 62, 1495\u20131506. https:\/\/doi.org\/10.3233\/JAD-171133 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR51","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737175.2023.2244162","volume":"23","author":"T Fulop","year":"2023","unstructured":"Fulop, T. et al. Viruses: A major cause of amyloid deposition in the brain. Expert Rev. Neurother. 23, 775\u2013790. https:\/\/doi.org\/10.1080\/14737175.2023.2244162 (2023).","journal-title":"Expert Rev. Neurother."},{"key":"10102_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway, J. M. et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457\u2013470. https:\/\/doi.org\/10.1038\/nrneurol.2015.119 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"10102_CR53","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333 (2023).","journal-title":"Brain"},{"key":"10102_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s00415-025-12996-3","volume":"272","author":"A Antonioni","year":"2025","unstructured":"Antonioni, A. et al. Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer\u2019s disease continuum. A systematic review and meta-analysis. J. Neurol. 272, 252. https:\/\/doi.org\/10.1007\/s00415-025-12996-3 (2025).","journal-title":"J. Neurol."},{"key":"10102_CR55","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41467-025-57144-7","volume":"16","author":"S Abu-Rumeileh","year":"2025","unstructured":"Abu-Rumeileh, S. et al. Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis. Nat. Commun. 16, 2019. https:\/\/doi.org\/10.1038\/s41467-025-57144-7 (2025).","journal-title":"Nat. Commun."},{"key":"10102_CR56","doi-asserted-by":"publisher","first-page":"fcae375","DOI":"10.1093\/braincomms\/fcae375","volume":"6","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. Plasma phosphorylated-tau217 is increased in Niemann\u2013Pick disease type C. Brain Commun. 6, fcae375. https:\/\/doi.org\/10.1093\/braincomms\/fcae375 (2024).","journal-title":"Brain Commun."},{"key":"10102_CR57","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80, 360\u2013369. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272 (2023).","journal-title":"JAMA Neurol."},{"key":"10102_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-024-01437-4","volume":"16","author":"JL Cantero","year":"2024","unstructured":"Cantero, J. L., Atienza, M., Sastre, I. & Bullido, M. J. Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging. Alzheimers Res Ther. 16, 68. https:\/\/doi.org\/10.1186\/s13195-024-01437-4 (2024).","journal-title":"Alzheimers Res Ther."},{"key":"10102_CR59","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3233\/JAD-230718","volume":"97","author":"E Vestin","year":"2024","unstructured":"Vestin, E. et al. Herpes simplex viral infection doubles the risk of dementia in a contemporary cohort of older adults: a prospective study. J. Alzheimers Dis. 97, 1841\u20131850. https:\/\/doi.org\/10.3233\/JAD-230718 (2024).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00905-5","volume":"13","author":"SY Huang","year":"2021","unstructured":"Huang, S. Y. et al. Herpesvirus infections and Alzheimer\u2019s disease: A Mendelian randomization study. Alzheimers Res. Ther. 13, 1\u20138. https:\/\/doi.org\/10.1186\/s13195-021-00905-5 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"10102_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JAD-160563","volume":"55","author":"SM Shim","year":"2016","unstructured":"Shim, S. M. et al. Elevated Epstein\u2013Barr virus antibody level is associated with cognitive decline in the Korean elderly. J. Alzheimers Dis. 55, 293\u2013301. https:\/\/doi.org\/10.3233\/JAD-160563 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR62","doi-asserted-by":"publisher","first-page":"e2252387","DOI":"10.1001\/jamanetworkopen.2022.52387","volume":"6","author":"H Stocker","year":"2023","unstructured":"Stocker, H. et al. Association of kidney function with development of Alzheimer Disease and other dementias and dementia-related blood biomarkers. JAMA Netw. Open 6, e2252387. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.52387 (2023).","journal-title":"JAMA Netw. Open"},{"key":"10102_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","volume":"17","author":"B Arslan","year":"2025","unstructured":"Arslan, B. et al. The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: Implications for predicting amyloid-\u03b2 positivity. Alzheimers Res. Ther. 17, 48. https:\/\/doi.org\/10.1186\/s13195-025-01692-z (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"10102_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3233\/JAD-161192","volume":"59","author":"P Bharadwaj","year":"2017","unstructured":"Bharadwaj, P. et al. The link between type 2 diabetes and neurodegeneration: Roles for amyloid-\u03b2, amylin, and tau proteins. J. Alzheimers Dis. 59, 421\u2013432. https:\/\/doi.org\/10.3233\/JAD-161192 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR65","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/brain\/awac354","volume":"146","author":"J van Arendonk","year":"2023","unstructured":"van Arendonk, J. et al. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study. Brain 146, 337\u2013348. https:\/\/doi.org\/10.1093\/brain\/awac354 (2023).","journal-title":"Brain"},{"key":"10102_CR66","doi-asserted-by":"publisher","first-page":"e0214151","DOI":"10.1371\/journal.pone.0214151","volume":"14","author":"H Chemaitelly","year":"2019","unstructured":"Chemaitelly, H., Nagelkerke, N., Omori, R. & Abu-Raddad, L. J. Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. PLoS ONE 14, e0214151. https:\/\/doi.org\/10.1371\/journal.pone.0214151 (2019).","journal-title":"PLoS ONE"},{"key":"10102_CR67","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-191092","volume":"73","author":"Q Cao","year":"2019","unstructured":"Cao, Q. et al. The prevalence of dementia: A systematic review and meta-analysis. J. Alzheimers Dis. 73, 1157\u20131166. https:\/\/doi.org\/10.3233\/JAD-191092 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"10102_CR68","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"10102_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2471\/BLT.19.237149","volume":"98","author":"C James","year":"2020","unstructured":"James, C. et al. Herpes simplex virus: Global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 98, 315\u2013329. https:\/\/doi.org\/10.2471\/BLT.19.237149 (2020).","journal-title":"Bull. World Health Organ."},{"key":"10102_CR70","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8 (2022).","journal-title":"Lancet Public Health"},{"key":"10102_CR71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"10102_CR72","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/clinchem\/41.7.1046","volume":"41","author":"PW Reymer","year":"1995","unstructured":"Reymer, P. W., Groenemeyer, B. E., Van de Burg, R. & Kastelein, J. J. Apolipoprotein E genotyping on agarose gels. Clin Chem. 41, 1046\u20131047 (1995).","journal-title":"Clin Chem."},{"key":"10102_CR73","volume-title":"Nonparametrics. Statistical Methods Based on Ranks","author":"EL Lehmann","year":"2006","unstructured":"Lehmann, E. L. Nonparametrics. Statistical Methods Based on Ranks 1st edn. (Springer, 2006).","edition":"1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10102-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:53:39Z","timestamp":1757238819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10102-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all study participants. All experiments were approved by the Minneapolis VAHCS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25475"}}